Journal
CARBOHYDRATE POLYMERS
Volume 135, Issue -, Pages 72-78Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.carbpol.2015.08.058
Keywords
Graphene oxide; Carboxymethyl chitosan; Hyaluronic acid; Doxorubicin; Targeted delivery; Controlled release
Categories
Funding
- Biomedical Textile Materials 111 Project from Ministry of Education of China [B07024]
- Langsha Group
- Jofo (WeiFang) Nonwoven Co. Ltd.
- UK-CHINA Joint Laboratory for Therapeutic Texiles
Ask authors/readers for more resources
In order to enhance the efficiency and specificity of anticancer drug delivery and realize intelligently controlled release, a new drug carrier was developed. Graphene oxide (GO) was first modified with carboxymethyl chitosan (CMC), followed by conjugation of hyaluronic acid (HA) and fluorescein isothiocyanate (FI). The resulting GO-CMC-FI-HA conjugate was characterized and used as a carrier to encapsulate the anticancer drug doxorubicin (DOX) to study in vitro release behavior. The drug loading capacity is as high as 95% and the drug release rate under tumor cell microenvironment of pH 5.8 is significantly higher than that under physiological conditions of pH 7.4. Cell uptake studies show that the GO-CMC-FI-HA/DOX complex can specifically target cancer cells, which are over-expressing CD44 receptors and effectively inhibit their growth. The above results suggest that the functionalized graphene-based material has potential applications for targeted delivery and controlled release of anticancer drugs. (C) 2015 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available